GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA.
Zacks Investment Research on MSN
GSK's chronic hepatitis B drug meets goals in two late-stage studies
GSK plc GSK announced positive results from two phase III studies, B-Well 1 and B-Well 2, which evaluated its investigational ...
Chronic hepatitis B (CHB) affects more than 254 million people globally, with 1.2 million new infections occurring each year. 1 And while it has the potential to cause severe long-term liver problems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback